V

ViroGates A/S
CSE:VIRO

Watchlist Manager
ViroGates A/S
CSE:VIRO
Watchlist
Price: 15.4 DKK -6.67% Market Closed
Market Cap: 119.1m DKK
Have any thoughts about
ViroGates A/S?
Write Note

ViroGates A/S
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ViroGates A/S
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
V
ViroGates A/S
CSE:VIRO
Net Issuance of Common Stock
kr13m
CAGR 3-Years
67%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GN Store Nord A/S
CSE:GN
Net Issuance of Common Stock
-kr12m
CAGR 3-Years
77%
CAGR 5-Years
61%
CAGR 10-Years
34%
Ambu A/S
CSE:AMBU B
Net Issuance of Common Stock
kr0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Demant A/S
CSE:DEMANT
Net Issuance of Common Stock
-kr2B
CAGR 3-Years
-3%
CAGR 5-Years
-12%
CAGR 10-Years
-15%
No Stocks Found

ViroGates A/S
Glance View

Market Cap
119.1m DKK
Industry
Health Care

ViroGates A/S develops and markets prognostic products for the healthcare sector. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.

VIRO Intrinsic Value
3.42 DKK
Overvaluation 78%
Intrinsic Value
Price
V

See Also

What is ViroGates A/S's Net Issuance of Common Stock?
Net Issuance of Common Stock
13m DKK

Based on the financial report for Sep 30, 2024, ViroGates A/S's Net Issuance of Common Stock amounts to 13m DKK.

What is ViroGates A/S's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 3Y
67%

The average annual Net Issuance of Common Stock growth rates for ViroGates A/S have been 67% over the past three years .

Back to Top